LAE112 / Laekna Therap - LARVOL DELTA

Laekna, Inc. (2105.HK) Announces Interim Results 2023 (PRNewswire) - "We have advanced three PCC drug candidates from our internal discovery platform: LAE111, a LILRB1 and LILRB2 bispecific antibody; LAE113, a TIGIT-PVRIG bispecific antibody; and LAE112, a FGFR2b monoclonal antibody....EXPECTED UPCOMING MILESTONES: (i) Presenting LAE111/LILRB1-2 bispecific antibody as a poster presentation at the Society for Immunotherapy of Cancer's (SITC) 38th annual meeting in San Diego, California, U.S., in November 2023; (ii) Presenting LAE113/TIGIT/PVRIG bispecific antibody as a poster presentation at the SITC 38th annual meeting in San Diego, California, U.S., in November 2023."

New molecule • Preclinical • Oncology